Microbiota and lipid mediators: from molecular crosstalk to therapeutic opportunities
Frontiers in Pharmacology · 16.07.2026 · 17
DOI: 10.3389/fphar.2026.1836931 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 16.07.2026. Verfasst von Büşra Başar Gökcen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutrition and Dietetics, Fethiye Faculty of Health Sciences, Muğla Sıtkı Koçman University, Muğla, Türkiye. Die Arbeit nennt 467 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The gut microbiota constitutes a metabolically active ecosystem that dynamically interacts with the host lipid metabolism and cellular signaling networks. While dietary lipids shape the microbial composition and metabolite production, the microbiota reciprocally biotransform fatty acids, thereby regulating lipid mediator bioavailability and host cellular responses. This bidirectional molecular crosstalk plays a pivotal role in maintaining metabolic homeostasis, epithelial barrier integrity, and immune regulation. Microbiota-derived lipid signals, including short-chain fatty acids, bile acids, polyunsaturated fatty acid-derived intermediates, sphingolipids, and N-acyl amides, modulate the balance between pro-inflammatory eicosanoids and specialized-pro resolving mediators. Through the engagement of G protein-coupled receptors, nuclear receptors such as Farnesoid X receptor and peroxisome proliferator activated receptors, Takeda G protein-coupled receptor 5, and the endocannabinoid system, these molecules influence gene expression, cytokine production, and cellular proliferation, thereby shaping the host physiology. Microbial enzymatic transformations, particularly bile acid biotransformation and fatty acid epoxide metabolism, further remodel the lipid mediator network and its biological effects. Disruption of this regulatory axis is associated with increased intestinal permeability, chronic low-grade inflammation, and metabolic dysfunction, contributing to the pathogenesis of metabolic syndrome, non-alcoholic fatty liver disease, inflammatory bowel diseases, and cardiometabolic disorders. From a therapeutic perspective, multicomponent interventions integrating probiotics, prebiotics, post-biotics, dietary modulation, and physical activity may rebalance the lipid mediator profiles and attenuate inflammatory burden. In this context, the microbiota–lipid mediator interface emerges as a translationally relevant biological target for the prevention and management of chronic diseases.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nutrition and Dietetics, Fethiye Faculty of Health Sciences, Muğla Sıtkı Koçman University, Muğla, Türkiye.
- Department of Nutrition and Dietetics, Faculty of Health Sciences, Karamanoğlu Mehmetbey University, Karaman, Türkiye.
- Department of Nutrition and Dietetics, Faculty of Health Sciences, Aydın Adnan Menderes University, Aydın, Türkiye.
- Department of Nutrition and Dietetics, Faculty of Health Sciences, Gazi University, Ankara, Türkiye.
- Department of Nutrition and Dietetics, Faculty of Health Sciences, Hitit University, Çorum, Türkiye.
- European Union and Foreign Affairs, Republic of Turkey Ministry of Health, Ankara, Türkiye.
Zitieren
APA
Başar Gökcen, B., Atabilen Pınar, B., Deniz Güneş, B., Çıtar Dazıroğlu, M. E., Duyar Özer, Ş., Biten, A. A., Pagano, E., Nanì, M. F., Romano, B., Ağagündüz, D., & Capasso, R. (2026). Microbiota and lipid mediators: from molecular crosstalk to therapeutic opportunities. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1836931
Vancouver
Başar Gökcen B, Atabilen Pınar B, Deniz Güneş B, Çıtar Dazıroğlu ME, Duyar Özer Ş, Biten AA, et al. Microbiota and lipid mediators: from molecular crosstalk to therapeutic opportunities. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1836931
BibTeX
@article{BaarGkcen2026,
author = {Başar Gökcen, Büşra and Atabilen Pınar, Büşra and Deniz Güneş, Burcu and Çıtar Dazıroğlu, Merve Esra and Duyar Özer, Şehriban and Biten, Aziz Alper and Pagano, Ester and Nanì, Maria Francesca and Romano, Barbara and Ağagündüz, Duygu and Capasso, Raffaele},
title = {Microbiota and lipid mediators: from molecular crosstalk to therapeutic opportunities},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1836931}
}
EUVIMED